Bicara Therapeutics (NASDAQ:BCAX) Reaches New 52-Week High – What’s Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX) hit a new 52-week high on Monday . The company traded as high as $28.00 and last traded at $27.9710, with a volume of 228286 shares changing hands. The stock had previously closed at $26.87.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BCAX shares. The Goldman Sachs Group raised their price objective on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Citizens Jmp reiterated a “market outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Wedbush reissued an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a report on Tuesday, March 31st. Wells Fargo & Company lifted their price target on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a report on Tuesday, March 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $30.27.

Bicara Therapeutics Trading Up 5.6%

The stock has a market capitalization of $1.86 billion, a P/E ratio of -10.20 and a beta of -0.54. The company’s 50-day moving average is $22.15 and its two-hundred day moving average is $19.34.

Bicara Therapeutics (NASDAQ:BCAX) last posted its earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Sell-side analysts expect that Bicara Therapeutics Inc. will post -3.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other Bicara Therapeutics news, CFO Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $20.42, for a total transaction of $187,864.00. Following the sale, the chief financial officer owned 145,355 shares of the company’s stock, valued at $2,968,149.10. The trade was a 5.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 12,500 shares of the business’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $23.01, for a total value of $287,625.00. Following the transaction, the chief operating officer owned 196,141 shares of the company’s stock, valued at $4,513,204.41. This trade represents a 5.99% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 63,900 shares of company stock valued at $1,420,704. Corporate insiders own 13.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Siren L.L.C. lifted its holdings in Bicara Therapeutics by 11.2% in the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock worth $115,421,000 after purchasing an additional 586,001 shares during the period. Vestal Point Capital LP increased its stake in Bicara Therapeutics by 2.0% during the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock valued at $80,529,000 after buying an additional 100,000 shares during the period. Janus Henderson Group PLC raised its position in shares of Bicara Therapeutics by 26.2% during the 1st quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock worth $66,350,000 after buying an additional 692,933 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after buying an additional 2,771,868 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Bicara Therapeutics by 9.8% in the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock valued at $34,753,000 after acquiring an additional 195,667 shares in the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.